Glutathione Injection

Adult dosage

Administer 1-2g of total amino acids/dipeptides per kg of body weight daily (0.17-0.34g as nitrogen) intravenously. This corresponds to 7-14mL of this drug per kg of body weight daily, and for a patient weighing 70kg, administer 500-1000mL daily. The infusion rate should ideally be 0.6-0.7mL per kg of body weight per hour (0.08-0.09g as total amino acids/dipeptides).

This drug must only be used according to a physician's instructions. It should not be used in patients with congenital metabolic disorders of amino acids, such as phenylketonuria. Patients with severe liver or kidney dysfunction should not take this drug. It should not be administered to patients who face life-threatening conditions due to severe cardiovascular problems. This drug is also unsuitable for patients with metabolic acidosis, i.e., those who have excessively high acidity in the body. It should not be used in patients with inadequate oxygen supply or excessive fluid in the body. Patients with low sodium or potassium levels in the blood should not be administered this drug. Patients with excessive lactic acid accumulation, i.e., lactic acidosis, should also avoid this drug. It is unsuitable for patients with heightened blood osmotic pressure. Patients with pulmonary edema from fluid accumulation in the lungs and those with severe cardiac failure should also avoid this drug. Patients who show allergic reactions to any of its components should not use it. This drug should not be administered to children under 2 years of age. Patients with a history of myocardial infarction or current myocardial infarction should also not use this drug. When administered correctly, no special side effects have been reported. However, if injected too quickly, discomfort, chills, nausea, vomiting, facial flushing, or sweating may occur. In such cases, the rate of drug administration should be reduced or temporarily stopped. There may be temporary liver function deterioration resulting in diarrhea, headache, paralysis, elevated body temperature, itching, or a sensation of heat. During the use of this drug, electrolyte concentrations, osmotic pressure, fluid balance in the body, acid-base status, and liver function levels should be regularly monitored. Currently, there are no known interactions with other drugs. Pregnant or lactating women may only use this drug if the therapeutic benefits are considered to outweigh the risks. Absolutely do not use in children under 2 years of age, and experience with children over 3 years old is limited, so it is not recommended. This drug should only be used when the container is undamaged and the solution is clear. Unused portions should not be reused. When storing this drug, soft bag products do not require a separate needle, while vial products should be prepared appropriately just before use, such as puncturing with an appropriate venting needle. Do not use if the solution is discolored, leaked, or if droplets are present on the packaging. Do not use if the film protecting the rubber stopper has been removed. When using the drug, the indicated measurement on the container must be strictly followed.

Mild side effects

• Chills, nausea, vomiting, flushing, sweating during rapid administration, symptoms of renal excretion of amino acids and dipeptides.
• Temporary elevation of liver enzymes causing diarrhea, headache, paralysis, elevated body temperature, itching, feeling of heat.

This drug should be stored in a sealed container that prevents air intrusion and is best kept at a cool temperature below 25 degrees Celsius. This will help maintain the drug's effectiveness and prevent deterioration.

Appearance

A colorless to pale yellow transparent liquid contained in a polypropylene aqueous injection bottle

Package unit

500mL/pack